Show simple item record

dc.contributor.authorKraby, Maria Ryssdal
dc.contributor.authorValla, Marit
dc.contributor.authorOpdahl, Signe
dc.contributor.authorHaugen, Olav Anton
dc.contributor.authorSawicka, Joanna Ewa
dc.contributor.authorEngstrøm, Monica J
dc.contributor.authorBofin, Anna M.
dc.date.accessioned2019-02-22T07:51:39Z
dc.date.available2019-02-22T07:51:39Z
dc.date.created2018-10-01T15:47:51Z
dc.date.issued2018
dc.identifier.citationBreast Cancer Research and Treatment. 2018, 1-14.nb_NO
dc.identifier.issn0167-6806
dc.identifier.urihttp://hdl.handle.net/11250/2586892
dc.description.abstractPurpose Androgen receptor (AR) expression is frequent in breast cancer and has been associated with good prognosis in several studies. The present study investigates AR-expression in relation to molecular subtypes, clinicopathological features and prognosis in 1297 primary tumours and 336 paired axillary lymph node metastases (LNM) from two cohorts of Norwegian patients. Methods Immunohistochemistry for AR was performed on tumours previously reclassified into molecular subtypes using immunohistochemistry and in situ hybridisation. Associations between AR-expression and clinical features were studied using Chi-square tests. Cumulative incidence of breast cancer death and Cox regression analyses were used to assess prognosis. Results AR-positivity was found in 78.0% of all cases, 84.9% of luminal and 45.1% of non-luminal tumours. The highest proportion of AR-positivity was found in Luminal B tumours, and the lowest in the Basal phenotype. Discordance in AR-status between primary tumours and lymph node metastases was observed in 21.4% of cases. A switch from AR− primary tumour to AR+ lymph node metastasis was seen in 60/72 discrepant cases. AR-expression in primary tumours was an independent and favourable prognostic marker (HR 0.70, 95% CI 0.55–0.90), particularly in the Luminal A subtype, and in grade 3 tumours. Conclusions AR is an independent predictor of good prognosis in BC, particularly in grade 3 and Luminal A tumours. Discordant AR-expression between primary tumour and LNM was observed in 21.4% of cases and most often there was a switch from AR− primary tumour to AR+ axillary LNM.nb_NO
dc.language.isoengnb_NO
dc.publisherSpringer Verlagnb_NO
dc.titleThe prognostic value of androgen receptors in breast cancer subtypesnb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionacceptedVersionnb_NO
dc.source.pagenumber1-14nb_NO
dc.source.journalBreast Cancer Research and Treatmentnb_NO
dc.identifier.doi10.1007/s10549-018-4904-x
dc.identifier.cristin1616877
dc.description.localcodeThis is a post-peer-review, pre-copyedit version of an article published in [Breast Cancer Research and Treatment] Locked until 14.8.2019 due to copyright restrictions. The final authenticated version is available online at: https://doi.org/10.1007/s10549-018-4904-xnb_NO
cristin.unitcode194,65,15,0
cristin.unitcode194,65,20,0
cristin.unitnameInstitutt for klinisk og molekylær medisin
cristin.unitnameInstitutt for samfunnsmedisin og sykepleie
cristin.ispublishedtrue
cristin.fulltextpostprint
cristin.qualitycode1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record